Cover Image

Secondary efficacy results from a phase 3 study comparing efficacy and safety of biosimilar candidate ABP 215 with bevacizumab in patients with non-squamous non-small cell lung cancer (NSCLC)

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: ABP 215 is a biosimilar candidate to bevacizumab, a VEGF inhibitor. Analytical, functional and p...

Full description

Saved in:
Bibliographic Details
Main Authors: Thatcher, Nicholas (Author) , Thomas, Michael (Author)
Format: Article (Journal)
Language:English
Published: 11 October 2016
In: Annals of oncology
Year: 2016, Volume: 27
ISSN:1569-8041
DOI:10.1093/annonc/mdw382.10
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw382.10
Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/1196P/2800055
Get full text
Author Notes:N. Thatcher, M. Thomas, G. Ostoros, J. Pan, J. Goldschmidt, V. Hanes
Description
Summary:© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: ABP 215 is a biosimilar candidate to bevacizumab, a VEGF inhibitor. Analytical, functional and pharmacokinetic similarity assessments between ABP 215 and bevacizumab have been completed. Here we present results of secondary efficacy variables, focusing on the risk difference (RD) of the overall response rate (ORR) and progression-free survival (PFS). Primary efficacy and safety results from this phase 3 study have been previously reported.Methods: In this randomized, double-blind, active-controlled study in adults with NSCLC receiving first-line chemotherapy with carboplatin and paclitaxel, patients were randomized (1:1) to receive 15 mg/kg of the investigational product (IP) (ABP 215 or bevacizumab) administered as an IV infusion every 3 weeks for 6 cycles. Patients remained on treatment until 21 days after the last dose of IP or...
Item Description:Gesehen am 14.11.2017
Physical Description:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdw382.10

Similar Items